Amphetamine News and Research RSS Feed - Amphetamine News and Research

Heavy marijuana use may lead to lower dopamine release in the brain

Heavy marijuana use may lead to lower dopamine release in the brain

In a recent study, researchers found evidence of a compromised dopamine system in heavy users of marijuana. Lower dopamine release was found in the striatum - a region of the brain that is involved in working memory, impulsive behavior, and attention. Previous studies have shown that addiction to other drugs of abuse, such as cocaine and heroin, have similar effects on dopamine release, but such evidence for cannabis was missing until now. [More]
ADHD stimulant drugs may lower bone density in children and adolescents

ADHD stimulant drugs may lower bone density in children and adolescents

Children and teenagers who take stimulant drugs to treat attention-deficit hyperactivity disorder (ADHD) may have lower bone density than their peers who do not take these medications, a new study finds. [More]
AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016. [More]
Misuse of Adderall drug rising among young adults, research suggests

Misuse of Adderall drug rising among young adults, research suggests

While the number of prescriptions for the stimulant Adderall has remained unchanged among young adults, misuse and emergency room visits related to the drug have risen dramatically in this group, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Drug use remains stable among teens, MTF survey shows

Drug use remains stable among teens, MTF survey shows

The 2015 Monitoring the Future survey (MTF) shows decreasing use of a number of substances, including cigarettes, alcohol, prescription opioid pain relievers, and synthetic cannabinoids ("synthetic marijuana"). Other drug use remains stable, including marijuana, with continued high rates of daily use reported among 12th graders, and ongoing declines in perception of its harms. [More]

Biophor receives FDA 510(k) clearance for distribution of seventh oral fluid screening assay

Biophor Diagnostics, Inc. announces that it has received FDA 510(k) clearance for sale and distribution of its seventh oral fluid screening assay based on the RapidFRET IVD Platform technology. This clearance completes the company's flagship panel for drugs of abuse screening in oral fluid. [More]
Glowing protein may replace fiber optic cable as light source in optogenetics research

Glowing protein may replace fiber optic cable as light source in optogenetics research

Optogenetics has taken neuroscience by storm in recent years because the technique allows scientists to study the brain conveniently in animals, activating or inhibiting selected groups of neurons at the flip of a switch. Most often, scientists use a fiber optic cable to deliver light into the brain. [More]
One in every 17 college students smokes marijuana on daily or near-daily basis

One in every 17 college students smokes marijuana on daily or near-daily basis

Daily marijuana use among the nation's college students is on the rise, surpassing daily cigarette smoking for the first time in 2014. [More]
AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI’s total revenue increases $89.5 million to 31% in second quarter 2015

AMRI today reported financial and operating results for the second quarter ended June 30, 2015. "We are very pleased to present another strong financial quarter, with all our divisions achieving excellent results," said William S. Marth, AMRI's president and chief executive officer. "Notably, recent acquisitions, combined with the cost reduction initiatives and efficiency efforts we've made to date, are contributing to continued strong contract margin performance. [More]
Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore Pharmaceuticals & Development, Inc. has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). [More]
New study examines how reasons for illicit marijuana use relate to use of other drugs

New study examines how reasons for illicit marijuana use relate to use of other drugs

Marijuana is the most prevalent drug in the U.S. Approximately 70% of the 2.8 million individuals who initiated use of illicit drugs in 2013 reported that marijuana was their first drug. [More]
Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
New technology can detect illegal drugs from a single fingerprint

New technology can detect illegal drugs from a single fingerprint

An innovative technology pioneered by Sheffield Hallam University academics can detect the presence of a range of illegal and designer drugs from a single fingerprint, which could be a valuable new tool in bringing drug dealers and other criminals to justice. [More]
FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. [More]
Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain. [More]

AMRI reports financial and operating results for Q4 and FY 2014

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2014. [More]
Altered dopamine signaling may contribute to autism

Altered dopamine signaling may contribute to autism

Newly discovered genetic variations linked to autism spectrum disorder (ASD) disrupt the function of the dopamine transporter, suggesting that altered dopamine signaling contributes to this common developmental condition, according to a Vanderbilt University-led research team. [More]
University of Copenhagen researchers move closer to developing antidote against cocaine addiction

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction. [More]
LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder." [More]
Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

Health Canada monitors recall of Jetfuel Superburn containing undeclared drug substances

"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). [More]
Advertisement
Advertisement